Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene


IRF8, a member of interferon regulatory factor (IRF) family of transcription factors is a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. TH17-cells are believed to be involved in the pathogenesis of various autoimmune/inflammatory diseases. These materials could be used to help define patterns of gene expression important for the development and function of cells including possible contributions to understanding: normal immune responses, inflammatory conditions, autoimmunity and anti-viral responses.

Potential Commercial Applications: Competitive Advantages:
  • Target identification in B and T cell deficiency, macrophage defects and hematopoiesis
  • A tool for investigating IRF8 mediated issues associated with inflammation and autoimmunity
  • Investigative tool for development of potential therapeutics for lymphoma and Human Chronic Myeloid Leukemia
 
  • Mice with established germ line transmission for use in conditional deletion of the IRF8 gene in any cellt type


Inventors:

Herbert Morse (NIAID)  ➽ more inventions...


Intellectual Property:

Publications:
Ouyang, Xinshou, et al. https://www.nature.com/articles/ncomms1311

Collaboration Opportunity:

The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop this technology by identifying pharmacological compounds inhibiting CD62L shedding by using high throughput compound screening. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.govor 1-240-627-3705.


Licensing Contact:
Christopher Kornak, J.D.
Email: chris.kornak@nih.gov
Phone: 240-627-3705

OTT Reference No: E-062-2012-0
Updated: Aug 27, 2019